The present protocol describes methods for evaluating DNA damage repair proteins in patient-derived ovarian cancer organoids. Included here are comprehensive plating and staining methods, as well as detailed, objective quantification procedures.
Immunofluorescence is one of the most widely used techniques to visualize target antigens with high sensitivity and specificity, allowing for the accurate identification and localization of proteins, glycans, and small molecules. While this technique is well-established in two-dimensional (2D) cell culture, less is known about its use in three-dimensional (3D) cell models. Ovarian cancer organoids are 3D tumor models that recapitulate tumor cell clonal heterogeneity, the tumor microenvironment, and cell-cell and cell-matrix interactions. Thus, they are superior to cell lines for the evaluation of drug sensitivity and functional biomarkers. Therefore, the ability to utilize immunofluorescence on primary ovarian cancer organoids is extremely beneficial in understanding the biology of this cancer. The current study describes the technique of immunofluorescence to detect DNA damage repair proteins in high-grade serous patient-derived ovarian cancer organoids (PDOs). After exposing the PDOs to ionizing radiation, immunofluorescence is performed on intact organoids to evaluate nuclear proteins as foci. Images are collected using z-stack imaging on confocal microscopy and analyzed using automated foci counting software. The described methods allow for the analysis of temporal and special recruitment of DNA damage repair proteins and colocalization of these proteins with cell-cycle markers.
Ovarian cancer is the leading cause of death due to gynecologic malignancy. The majority of patients are treated with DNA-damaging drugs such as carboplatin, and those with homologous recombination repair (HRR)-deficient tumors can be given poly (ADP-ribose) polymerase (PARP) inhibitors1,2. However, most patients develop resistance to these therapies and die within 5 years of diagnosis. Dysregulation of the DNA damage response (DDR) has been associated with the development of ovarian cancer and both chemotherapy and PARP inhibitor resistance3. Thus, study of the DDR is imperative in understanding the pathophysiology of ovarian cancer, potential biomarkers, and novel targeted therapies.
Current methods to evaluate the DDR utilize immunofluorescence (IF), as this allows for the accurate identification and localization of DNA damage proteins and nucleotide analogs. Once there is a double-stranded break (DSB) in the DNA, the histone protein H2AX is rapidly phosphorylated, forming a focus where DNA damage repair proteins congregate4. This phosphorylation can be easily identified utilizing IF; in fact, the ɣ-H2AX assay has commonly been employed to confirm the induction of a DSB5,6,7,8,9. Increased DNA damage has been associated with platinum sensitivity and efficacy of DNA damaging agents10,11,12, and ɣ-H2AX has been proposed as a biomarker associated with chemotherapy response in other cancer treatments13. Upon a DSB, a cell proficient in HRR performs a series of events that leads to BRCA1 and BRCA2 recruiting RAD51 to replace replication protein A (RPA) and bind to the DNA. HRR repair uses a DNA template to faithfully repair the DSB. However, when tumors are deficient in HRR, they rely on alternative repair pathways such as non-homologous end joining (NHEJ). NHEJ is known to be error-prone and creates a high mutational burden on the cell, which uses 53BP1 as a positive regulator14. These DNA damage proteins can all be accurately identified as foci using IF. In addition to staining for proteins, IF can be used to study fork protection and single-stranded DNA gap formation. The ability to have stable forks has been correlated with platinum response, and recently, gap assays have shown the potential to predict the response to PARP inhibitors6,15,16,17. Therefore, staining for the nucleotide analogs after introduction into the genome is another way to study the DDR.
To date, evaluation of the DDR in ovarian cancer has been largely limited to homogenous 2D cell lines that do not recapitulate the clonal heterogeneity, microenvironment, or architecture of in vivo tumors18,19. Recent research suggests organoids are superior to 2D cell lines in studying complex biologic processes such as DDR mechanisms6. The present methodology evaluates RAD51, ɣ-H2AX, 53BP1, RPA, and geminin in PDOs. These methods assess the intact organoid and allow for the study of DDR mechanisms in a setting more similar to the in vivo tumor microenvironment. Together with confocal microscopy and automated foci counting, this methodology can aid in understanding the DDR pathway in ovarian cancer and personalizing treatment plans for patients.
Tumor tissue and ascites were obtained after obtaining patient consent as part of a gynecologic oncology biorepository that was approved by the Washington University in St. Louis Institutional Review Board (IRB). Patients were included if they had advanced stage high-grade serous ovarian cancer (HGSOC). All procedures were performed at room temperature on the bench unless otherwise specified. All reagents were prepared at room temperature (unless otherwise indicated) and stored at 4 °C.
1. Organoid generation
2. Plating and irradiation of organoids
3. Immunofluorescence staining
NOTE: Volumes refer to the amount per well of the 8-well chamber slide (~300 µL).
4. Imaging
5. Analysis
NOTE: Use JCountPro for all image analysis following the previously published report21. To obtain this software, reference the associated publication.
The presented protocol can successfully stain, visualize, and quantify nuclear DNA damage repair proteins in organoids. This technique was used to stain and evaluate PDOs both before and after irradiation. PDOs were exposed to 10 Gy of radiation and evaluated for the following biomarkers: ɣ-H2AX (Figure 1), a marker of DNA damage; RAD51 (Figure 2), a marker for HRR; 53BP1, a marker of NHEJ; RPA, a marker of replication stress (Figure 3); and geminin, a G2/S phase cell cycle marker14. The dose of 10 Gy was chosen based on previously published research studying DNA damage in ovarian cancer6,22. JCountPro software was used to identify the nucleus and quantify the number of foci within the nucleus with illustrated parameters13 (Figure 4). The software identifies the nucleus (Figure 4A,B), then nuclear foci (Figure 4C), and filters the foci from geminin-positive cells (Figure 4D).
Figure 1: ɣ-H2AX foci in PDOs before and after irradiation. Representative images of DAPI and ɣ-H2AX foci in PDOs before and after irradiation at 10x with 63x insets. Scale bars: 10 µm. Please click here to view a larger version of this figure.
Figure 2: RAD51 foci and geminin in PDOs before and after irradiation. Representative images of DAPI, geminin, RAD51, and co-staining of geminin/RAD51 foci PDOs before and after irradiation at 10x with 63x insets. Scale bars: 10 µm. Please click here to view a larger version of this figure.
Figure 3: RPA and 53BP1 in PDOs before and after irradiation. Representative images of (A) DAPI, RPA; (B) geminin, 53BP1, and co-staining of geminin/53BP1 foci at 10x with 63x insets. Scale bars: 10 µm. Please click here to view a larger version of this figure.
Figure 4: The JCountPro software quantification workflow. (A) Under the object analysis, the blue channel is selected to identify the blue objects, nuclei, then it is automatically optimized by selecting the auto segmentation (red arrow). (B) Under auto split, the object size (nuclei) is adapted to the size of the image and magnification. The identify object button is selected to test the parameters (1), and the identify objects in all images (red arrow) button is selected to identify objects (nuclei) for each image. (C) Under the foci analysis tab, the images are inputted and the foci counting parameters are set: first, the color of the foci is selected under the focus channel, green; the top hat index is set to 12; the H dome settings are set to have a dome height percentage of 30 and a threshold percentage of 28; the shape and size of the foci are optimized to the image size with the manual parameters of maximum focus size pixels at 60 and minimum roundness x 100 at 96; finally, the noise filter is applied. The settings are tested by applying the top hat, H dome, and foci count (1-3). To quantify the ɣ-H2AX foci per cell, press start (red arrow). (D) For the RAD51 foci, the settings are applied as illustrated for ɣ-H2AX foci, except the focus channel which is changed to red; however, to identify nuclei that are stained with geminin, the second channel is selected for green, and analysis is changed to intensity. The parameters are tested by applying the top hat, H dome, and foci count (1-3), then pressing start (red arrow) to quantify all RAD51 foci and evaluating the intensity of green per cell in each image. Scale bar: 10 µm. Please click here to view a larger version of this figure.
The DNA damage response plays an integral role in both the development of ovarian cancer and chemotherapy resistance. Therefore, a thorough understanding of DNA repair mechanisms is imperative. Here, a methodology is presented to study DNA damage repair proteins in 3D, intact organoids. A reproducible, reliable protocol is developed utilizing hallmark antibodies to evaluate DNA damage, homologous recombination, non-homologous end joining, and replication stress. Importantly, these methods are validated using genetically modified controls demonstrating the specificity and sensitivity of these methods.
The most critical step in this protocol is the plating and fixation of the organoids. This protocol specifically incubates organoids in 2% PFA for 10 min with close monitoring of the basement membrane extract (BME) during the fixation process. This differs from other immunofluorescence protocols in organoids that suggest using 4% PFA for 10-60 min23,24,25. It has been found that if the tabs of the BME are in a concentrated amount of PFA for too long, the tabs depolymerize and are subject to aspiration. Of note, manufacturers of specific BMEs often offer suggestions regarding fixation. Another important point of discussion is the plating of the organoids. The staining process can result in losing a portion or all of the organoids. Therefore, the more confluent the tab at the time of plating, the higher likelihood the sample will successfully withstand the steps of staining.
The strengths of this protocol include the validation of nuclear antibody staining, the ability to perform immunofluorescence and imaging of intact 3D organoids, and the adaptability of the protocol to any treatment or molecule of interest.
The antibodies used in these experiments were stringently validated for specificity using genetically modified ovarian cancer cells. The methods were further validated for sensitivity by exposing PDOs to increasing doses of radiation. This resulted in increasing ɣ-H2AX, RAD51, and RPA foci in HRR-proficient PDOs. Lastly, the objective quantification methods facilitate the reproducibility of this assay and avoid the subjective bias of manual quantification.
Traditional methods to explore the DDR are through 2D culturing conditions known as cell lines, but they do not have the ability to maintain the genetic heterogeneity of the original tumor. The tumor microenvironment is vital in tumorigenesis and chemotherapy resistance in ovarian cancer26,27,28, therefore, these models offer an advantage to 2D homogenous cell cultures when studying the DDR. When studying the DDR, it is necessary to control for cell cycle in order to avoid misclassification of the inability to perform specific types of DNA repair that are cell cycle specific (i.e., HRR). Future work is focused on studying specific types of DNA lesions caused by platinum chemotherapy, poly (ADP-ribose) polymerase inhibitors, or hydroxyurea.
Lastly, this protocol is adaptable to study any antigen amendable to traditional immunofluorescence and can accommodate the study of novel drug therapies. The protocol presented focuses on DDR proteins, but with a simple change of antibodies, this protocol can be modified to study other proteins, glycans, and small molecules. Additionally, as the organoids are heterogenous 3D models cultured in vitro, any treatment of the organoids is possible, including immunotherapy, antiangiogenic therapy, metabolomics therapy, and other novel therapies that are difficult to evaluate in homogenous cell lines29,30,31.
Limitations of this method include using a BME with inconsistent composition and non-specific staining. As commercial BMEs are produced from cell lines, the composition of each unit can vary tremendously. These differences could affect the fixation and staining, as well as organoid generation. Additionally, depending on the sample, there can be non-specific staining of the BME, which can obstruct the protein of interest. Nonetheless, the nuclear staining is very specific and demonstrates clear nuclear foci which can be easily quantified.
In conclusion, a detailed protocol to evaluate DDR proteins in organoids is presented. As technology advances, it is anticipated that organoids will be able to be used to evaluate live cell DNA damage repair in these 3D models. Additionally, as the most effective method to culture, the organoids will be established, and more sophisticated assays such as DNA fiber and replication gap assays will be possible32.
The authors have nothing to disclose.
We are grateful for the guidance of Pavel Lobachevsky, PhD in establishing this protocol. We'd also like to acknowledge Washington University's School of Medicine in St. Louis's Department of Obstetrics and Gynecology and Division of Gynecologic Oncology, Washington University's Dean's Scholar Program, Gynecologic Oncology Group Foundation, and the Reproductive Scientist Development Program for their support of this project.
1x phosphate buffered saline with calcium and magnesium (PBS++) | Sigma | 14-040-133 | |
1x phosphate buffered saline without calcium and magnesium (PBS) | Fisher Scientific | ICN1860454 | |
Ant-53BP1 Antibody | BD Biosciences | 612522 | diluted to 1:500 in staining buffer |
Ant-Geminin Antibody | Abcam | ab104306 | diluted to 1:200 in staining buffer |
Anti-Geminin Antibody | ProteinTech | 10802-1-AP | diluted to 1:400 in staining buffer |
Anti-RAD51 Antibody | Abcam | ab133534 | diluted to 1:1000 in staining buffer |
Anti-yH2AX Antibody | Millipore-Sigma | 05-636 | diluted to 1:500 in staining buffer |
Ant-phospho-RPA32 (S4/S8) Antibody | Bethyl Laboratories | A300-245A-M | diluted to 1:200 in staining buffer |
Bovine Serum Albumin (BSA) | Fisher Scientific | BP1605 100 | |
Centrifuge; Sorvall St 16R Centrifuge | Thermo Scientific | 75004240 | |
Confocal Microscope, Leica SP5 confocal system DMI4000 | Leica | 389584 | |
Conical Tubes, 15 mL | Corning | 14-959-53A | |
Countess 3 FL Automated Cell Counter (Cell Counting Machine) | Thermo Scientific | AMQAF2000 | |
Countess Cell Counting Chamber Slides | Thermo Scientific | C10228 | |
Cover Slip | LA Colors | Any clear nail polish will suffice | |
Cultrex RGF Basement Membrane Extract, Type 2 | R&D Systems | 3533-010-02 | Could probably use Matrigel or other BME Matrix |
DAPI | Thermo Scientific | R37606 | NucBlue Fixed Cell ReadyProbes Reagent, Diluted in 1x PBS |
Glycine | Fisher Scientific | NC0756056 | |
JCountPro | JCountPro | For access to the software, Email: jcountpro@gmail.com | |
Microcentrifuge Tubes | Fisher Scientific | 07-000-243 | |
Nail Polish | StatLab | SL102450 | |
Parafomraldehyde (PFA), 2% | Electron Microscopy Sciences | 157-4 | Dilute to 4% PFA in PBS++ to obtain 2% PFA |
Permeabilization Buffer | Made in Lab | 0.2% X-100 Triton in PBS++ | |
Pipette | Rainin | 17014382 | |
Pipette Tips | Rainin | 17014967 | |
ProLong Gold Antifade Mountant | Thermo Scientific | P36930 | |
Staining Buffer | Made in Lab | 0.5% BSA, 0.15% Glycine, 0.1% X-100 Triton in PBS++ | |
Thermo Scientific Nunc Lab-Tek II Chamber Slide System | Thermo Scientific | 12-565-8 | |
Triton X-100 | Sigma-Alderich | 11332481001 | |
Trypan Blue Solution, 0.4% | Thermo Scientific | 15250061 | |
TrypLE Express | Invitrogen | 12604013 | animal origin-free, recombinant enzyme |
X-RAD 320 Biological Irradiator | Precision X-Ray Irradiation | X-RAD320 |